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Structural characterization of clusterin-chaperone client protein complexes
Abstract
Clusterin (CLU) is a potent extracellular chaperone that inhibits protein aggregation and precipitation
otherwise caused by physical or chemical stresses (e.g. heat, reduction). This action involves CLU
forming soluble high molecular weight (HMW) complexes with the client protein. Other than their
unquantified large size, the physical characteristics of these complexes were previously unknown. In this
study, HMW CLU-citrate synthase (CS), HMW CLU-fibrinogen (FGN), and HMW CLU-glutathione
S-transferase (GST) complexes were generated in vitro, and their structures studied using size exclusion
chromatography (SEC), ELISA, SDS-PAGE, dynamic light scattering (DLS), bisANS fluorescence, and
circular dichroism spectrophotometry (CD). Densitometry of Coomassie Blue-stained SDS-PAGE gels
indicated that all three HMW CLU-client protein complexes had an approximate mass ratio of 1:2
(CLU:client protein). SEC indicated that all three clients formed complexes with CLU ≥ 4 × 107 Da;
however, DLS estimated HMW CLU-FGN to have a diameter of 108.57 ± 18.09 nm, while HMW CLU-CS and
HMW CLU-GST were smaller with estimated diameters of 51.06 ± 6.87 nm and 52.61 ± 7.71 nm,
respectively. Measurements of bisANS fluorescence suggest that the chaperone action of CLU involves
preventing the exposure to aqueous solvent of hydrophobic regions that are normally exposed by the
client protein during heat-induced unfolding. CD analysis indicated that, depending on the individual client
protein, CLU may interact with a variety of intermediates on protein unfolding pathways with different
amounts of native secondary structure. In vivo, soluble complexes like those studied here are likely to
serve as vehicles to dispose of otherwise dangerous aggregation-prone misfolded extracellular proteins.
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Clusterin (CLU) is a potent extracellular
chaperone that inhibits protein aggregation
and precipitation otherwise caused by physical
or chemical stresses (e.g. heat, reduction). This
action involves CLU forming soluble high
molecular weight (HMW) complexes with the
client protein. Other than their unquantified
large size, the physical characteristics of these
complexes were previously unknown. In this
study, HMW CLU-citrate synthase (CS),
HMW
CLU-fibrinogen
(FGN)
and
HMW CLU-glutathione-S-transferase (GST)
complexes were generated in vitro and their
structures studied using size exclusion
chromatography (SEC), ELISA, SDS-PAGE,
dynamic light scattering (DLS), bisANS
fluorescence,
and
circular
dichroism
spectrophotometry (CD). Densitometry of
Coomassie-stained SDS-PAGE gels indicated
that all three HMW CLU-client protein
complexes had an approximate mass ratio of
1:2 (CLU:client protein). SEC indicated that
all three clients formed complexes with CLU
 4 x 107 Da, however, DLS estimated
HMW CLU-FGN to have a diameter of
108.57 ± 18.09, while HMW CLU-CS and
HMW CLU-GST were smaller with estimated
diameters of 51.06 ± 6.87 nm and
52.61 ± 7.71 nm, respectively. Measurements
of bisANS fluorescence suggest that the
chaperone action of CLU involves preventing
the exposure to aqueous solvent of
hydrophobic regions that are normally
exposed by the client protein during
heat-induced unfolding. CD analysis indicated
that, depending on the individual client
protein, CLU may interact with a variety of
intermediates on protein unfolding pathways
with different amounts of native secondary
structure. In vivo, soluble complexes like those
studied here are likely to serve as vehicles to

dispose of otherwise dangerous aggregationprone misfolded extracellular proteins.
Controlled unfolding is important in
many biological processes including protein
translocation, degradation by proteases and
regulation of enzyme activity. Uncontrolled
unfolding and the consequent accumulation of
insoluble protein aggregates is implicated in the
pathology
of
many
diseases
including
Alzheimer’s disease and type II diabetes and is
promoted by various stresses such as oxidative
stress (1), shear stress (2) and thermal stress (3).
Cells have extensive quality control mechanisms
to ensure that intracellular proteins are maintained
predominantly in their native conformations.
Molecular chaperones are known to play a central
role in these systems by targeting unfolded
proteins for refolding or degradation (4-7).
However, little is known about the existence of
corresponding systems for protein folding quality
control in the extracellular environment (8).
A large number of alternative functions
have been proposed for clusterin (CLU),
nevertheless, the potent chaperone activity of this
protein (9-13) and its constitutive presence in
many biological fluids suggests that it is likely to
be important in extracellular protein folding
quality control. Recently haptoglobin (14) and 2macroglobulin (15,16) have also been identified
as extracellular chaperones. All three proteins
exhibit small heat shock protein (sHsp)-like
activity, preferentially binding to stressed client
proteins to prevent their precipitation in an ATPindependent manner (9,11,14,16). When acting
alone, extracellular chaperones lack refolding
activity, however it has been shown that CLU can
hold partially unfolded proteins in a state
competent for refolding by Hsc70 (11).
CLU
is
found
associated
with
extracellular protein deposits in numerous
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diseases including drusen in age-related macular
degeneration (17), renal immunoglobulin deposits
in kidney disease (18), Lewy bodies in
Parkinson’s disease (19), prion deposits in
Creutzfeldt-Jakob disease (20) and amyloid
plaques in Alzheimer’s disease (21). Knock-out
studies have shown that CLU-deficient mice
accumulate insoluble protein deposits in the
kidneys and develop progressive glomerulopathy
(22). These findings suggest a role for CLU in the
clearance of extracellular misfolded proteins,
however, the mechanism by which this may occur
has yet to be determined.
Currently, little is known about the
physical characteristics of the soluble complexes
formed during the interaction of CLU with
chaperone client proteins (9-12). This is the first
study to investigate the physical properties of
CLU-client protein complexes. The present study
provides new insights into the properties of
complexes formed in vitro between CLU and
citrate synthase (CS), fibrinogen (FGN) and
glutathione-S-transferase (GST).

3.2 μM, respectively) or the control protein, BSA
(at the same respective molar concentrations). The
solutions were added in triplicate 100 μl aliquots
to a 384 well plate (Greiner Bio-one). Protein
precipitation was monitored by measuring the
absorbance at 360 nm (A360 nm; an indication of
turbidity) with a FLUOstar Optima incubator
microplate reader (BMG Labtechnologies).
Preparation of Preheated Protein
Controls - Preheated control proteins were
prepared by incubating client proteins or CLU
(alone) at the same temperature and for the same
duration used to form the HMW complexes.
Preheated controls were filtered (0.45 μm) and the
clarified solutions assayed for residual protein
content using the bicinchoninic micro-protein
assay (25), or the respective extinction
coefficients at 280 nm.
Size Exclusion Chromatography (SEC) SEC was carried out using a SuperoseTM 6 10/300
column (GE Healthcare) at the recommended
flow rate of 0.5 ml/min and the absorbance at
280 nm continuously monitored using an ÄKTA
FPLC system (GE Healthcare). Mass standards
were from a commercial high molecular weight
calibration kit (GE Healthcare). All buffers and
samples were filtered (0.45 μm) before use. SEC
purified HMW complexes were collected from
fractions between 7-8 ml in the peak
corresponding to the size exclusion limit of
 4 x 107 Da. The integrity of the complexes was
checked periodically by reanalysis using the same
column.
Sandwich ELISA - The wells of an
ELISA plate (Greiner Bio-one) were coated with
purified G7 anti-CLU antibody (23), then blocked
with 1% (w/v) BSA in PBS (BSA/PBS). Mixtures
of CLU and client protein were heated as
described in Precipitation Assays and fractionated
by SEC (as described above). After washing with
PBS, proteins eluting at the exclusion limit
( 4 x 107 Da), preheated CLU or client proteins,
or a mixtures of CLU and individual client
proteins were incubated in the wells of the ELISA
plate (diluted to 50 μg/ml in BSA/PBS). Then a
primary antibody (or antiserum) reactive with the
client protein, diluted in BSA/PBS, was added
following the manufacturer’s instructions. Finally
an appropriate horseradish peroxidase conjugated
secondary antibody diluted in BSA/PBS was

EXPERIMENTAL PROCEDURES
Materials - 4,4’-Bis(1-anilino-8-naphthalene
sulfonate; bisANS), bovine serum albumin
(BSA), CS, and FGN were all obtained from
Sigma-Aldrich. All buffer salts and H2O2 were
obtained from Ajax Chemical Co. Human blood
was obtained as a kind gift from Wollongong
Hospital (Wollongong, NSW, Australia) and
processed to yield plasma, which was stored
frozen at -20ºC until used. CLU was purified
from human plasma by immunoaffinity
chromatography as previously described (23).
GST was expressed in E. coli using the vector
pGEX-2T (without an insert; Invitrogen) as
previously described (24) and purified using a
Glutathione SepharoseTM High Performance
column according to the manufacturer’s
directions (GE Healthcare).
Precipitation Assays - CS (6.0 μM), FGN
(6.0 μM) or GST (20 μM) were incubated at
41ºC, 45ºC or 60ºC, respectively, in phosphate
buffered saline (PBS; 137 mM NaCl, 2.7 mM
KCl, 1.5 mM KH2PO4, and 8 mM Na2 HPO4, pH
7.4) containing 0.1% (w/v) NaN3 (PBS/Az) in the
presence or absence of CLU (6.6 μM, 6.5 μM and
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added following the manufacturer’s instructions.
All incubations were carried out for 1 h at 37ºC
with shaking and washing was performed with
PBS. After a final wash, ortho-phenylenediamine
at 2.5 mg/ml in 50 mM citric acid, 100 mM
Na2 HPO4, pH 5, was added. The absorbance at
490 nm (A490 nm) was measured using a
SpectraMax Plus384 microplate reader (Molecular
Devices). Non-specific binding was assessed
using a species–matched polyclonal antibody or
serum of irrelevant specificity and the appropriate
secondary antibody. Primary antibodies used
were sheep polyclonal anti-CS (IgG fraction,
Abcam), goat anti-FGN antiserum and rabbit
polyclonal anti-GST (IgG fraction, Chemicon).
The respective controls were polyclonal antiApolipoprotein A1 (IgG fraction, Abcam),
normal goat serum (Sigma-Aldrich) and purified
normal rabbit IgG fraction (Sigma-Aldrich).
Dynamic Light Scattering (DLS) Solutions of SEC purified HMW CLU-CS, HMW
CLU-FGN and HMW CLU-GST complexes,
CLU, FGN, CS or GST (controls were preheated
or untreated), or mixtures of these proteins, were
made between 0.1-1.0 mg/ml in PBS and filtered
(0.45 μm). Triplicate samples were examined in
low volume plastic cuvettes using a Zetasizer
Nano ZS (Malvern). Particle diameters were
recorded as a frequency distribution curve and the
average diameter and range (average peak and
width of 9 normally distributed curves) reported.
Densitometry - Several mg of CS, FGN,
GST or CLU were extensively dialyzed against
distilled water and then freeze-dried. The
recovered protein was weighed using a XS205
Dual Range analytical balance (Mettler Toledo).
The proteins were redissolved in an appropriate
volume of filtered (0.45 μm) PBS and the
absorbance at 280 nm of several aliquots
measured using a SpectraMax Plus 384
microplate reader (Molecular Devices). The
average absorbance at 280 nm and the known
protein concentration were used to calculate the
extinction coefficient using Beer’s law. These
proteins, as well as SEC purified HMW CLU-CS,
HMW CLU-FGN and HMW CLU-GST
complexes were reduced by boiling in SDSPAGE loading buffer containing 100 mM
dithiothreitol and 1 % (v/v) -mercaptoethanol
and separated on a 12 % SDS gel. Six sample
wells containing unknown amounts of reduced

HMW CLU-CS, HMW CLU-FGN or HMW
CLU-GST complexes and triplicate wells
containing 0.5-6 μg of reduced CS, FGN, GST or
CLU were also loaded onto the gel. Following
Coomassie blue staining and destaining, the major
bands corresponding to reduced CS, FGN, GST
and CLU were analyzed using a GS 800
calibrated densitometer (Bio-Rad) and Quantity
One software (Bio-Rad). The average optical
density/mm2 of the major bands was used to
construct a standard curve for each protein. Using
these standard curves, the relative amounts of
CLU and FGN, CS or GST present in the SEC
purified HMW complexes were calculated.
4,4-Dianilino-1,1-binaphthyl-5,5disulfonic acid (bisANS) - For bisANS analyses,
CLU client proteins (0.5 mg/ml CS,
2 mg/ml FGN, or 0.5 mg/ml GST), or mixtures of
client proteins (at the same concentrations) and
CLU (at 0.4 mg/ml for experiments using CS or
FGN, or at 0.2 mg/ml for experiments using GST)
were incubated under the same conditions used to
form HMW CLU-client protein complexes (see
above). At specified time points, samples were
taken from the solutions and snap frozen in liquid
nitrogen. Following completion of the time
courses, all samples were thawed and
immediately diluted in PBS containing bisANS to
give final concentrations of 50 μg/ml client
protein and 10 μM bisANS. Samples containing
CLU alone were diluted to give equivalent
concentrations to that present in the (CLU + client
protein) samples (i.e. 15 μg/ml or 30 μg/ml).
Fluorescence was measured on a FLUOstar
Optima fluorescence plate reader using excitation
and emission windows of 360 +/-10 and
490 +/-10 nm, respectively.
Circular Dichroism (CD) - For CD
analyses, samples were analyzed as previously
described (26); all samples were in 10 mM
Na2 HPO4, pH 7.4. Individual proteins were
analyzed before and after heating (the latter were
residual soluble protein) at the following
concentrations: CLU at 164 μg/ml, CS at 119
μg/ml, FGN at 164 μg/ml, and GST at 110 μg/ml.
In separate experiments, spectra were acquired for
HMW complexes of CLU-CS (119 μg/ml), CLUFGN (164 μg/ml), CLU-GST (110 μg/ml), and
solutions of CLU or the individual client proteins
at concentrations corresponding to those present
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in the complexes analyzed (calculated on the basis
of the mass ratios of CLU:client protein in the
complexes). Estimates of secondary structure
were obtained using the program CDSSTR (27).
Thioflavin T Analyses - For thioflavin T
fluorescence assays, all samples were prepared at
50 μg/ml in PBS and contained 62.5 μM
thioflavin T; fluorescence was measured using a
FLUOstar Optima microplate reader (BMG
Labtechnologies), with an excitation wavelength
of 440 nm and an emission wavelength of 490 nm
(slit-width 10 nm). Lysozyme amyloid was
formed as described in (28).

incubated alone at 41-60ºC (data only shown for
60ºC; Fig. 1C). As first reported by Humphreys et
al. (1999) the effect of CLU on protein
precipitation was dose-dependent for all client
proteins (data not shown).
Production
of
Preheated
Protein
Controls. To produce preheated protein controls,
solutions of individual proteins were heated as
described above and insoluble protein removed by
filtration through a 0.45 μm filter. There was no
difference in the SEC profiles of unheated
CS, FGN, GST or CLU and the residual
corresponding proteins remaining in solution after
the respective heat treatments (Fig. 2). Also, when
the residual, soluble heat-treated proteins were
mixed, very little interaction was detected by SEC
between CLU and CS (Fig. 2A), CLU and FGN
(Fig. 2B), or CLU and GST (Fig. 2C).
Detection of HMW complexes by SEC.
SEC fractionation of the heat stressed mixtures of
CLU and CS (41ºC), CLU and FGN (45ºC) or
CLU and GST (60ºC) showed that they contained
HMW species eluting at the exclusion limit of the
column ( 4 x 107 Da) that were absent from the
same mixtures left unheated, and from solutions
of the individual proteins (Fig. 2). Compared to
FGN and GST, co-incubation of CS with CLU at
41ºC produced proportionally less HMW species,
however, it was evident that complexes
comparable in mass to those formed at higher
temperatures by CLU and FGN or GST were also
formed by CLU and CS. The exclusion limit peak
was collected in each case and represented
putative HMW CLU-client protein complexes.
The identity of these complexes was confirmed by
sandwich ELISA (see below). These complexes
were stored in PBS/Az at 4ºC and their integrity
checked at intervals by SEC; under these
conditions they remained stable for months.
Sandwich ELISA to Confirm the Identity
of CLU-Client Protein Complexes. Sandwich
ELISA designed to capture CLU and
subsequently detect CS, FGN or GST was used to
confirm the identity of the putative complexes
purified by SEC. Relative to the samples
containing the HMW complexes, little
absorbance was obtained for control samples
(Fig. 3).
Estimates of Stoichiometry Within
Complexes. To estimate the stoichiometry of
individual proteins within the HMW complexes,

RESULTS
In Vitro Formation of CLU-Client
Protein Complexes. When incubated alone at
41ºC, 6 μM CS showed a progressive increase in
turbidity (increasing A360 nm; Fig. 1A) from 0 to
about 500 min. No further increase in turbidity
was observed after approximately 500 min. Under
the same conditions, when CLU was present with
CS at a near equimolar concentration, no
increases in turbidity were detected, indicating
that CS was stabilized in solution. At the same
concentration BSA had little effect on the
precipitation of CS. Incubation of FGN alone at
45°C resulted in progressive precipitation of the
protein after an initial lag phase of approximately
200 min - no further increases in turbidity were
measured after 800 min (Fig. 1B). Under the
same conditions, co-incubation of 6.5 μM CLU
with 6.0 μM FGN completely abolished any
increase in turbidity; in contrast, 6.5 mM BSA
had little effect on the precipitation of FGN.
Incubation of 20 μM GST at 60°C resulted in
rapid precipitation of the protein after a lag phase
of approximately 25 min (Fig. 1C). After 40 min
the protein solution reached maximum turbidity
and prolonged heating had no further effect. Coincubation of 20 μM GST with 3.2 μM CLU
almost completely inhibited the precipitation of
GST under the same conditions. This was in
contrast to co-incubation with 3.2 μM BSA,
where the protein solution exhibited a similar
precipitation profile to that observed when GST
was incubated alone. However, the maximum
turbidity was marginally less in the presence of
BSA. Both CLU and BSA were stable when
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SEC purified complexes were separated by
SDS-PAGE under reducing conditions, the gels
stained with Coomassie blue, and the intensity
of individual protein bands quantified by
densitometry. After standard curves were
generated for each protein, the approximate mass
ratios and molar ratios for each complex were
calculated. The mass ratio of CLU to client
protein was similar for CS, FGN and GST
complexes (about 1:2 in each case). However, the
molar ratios were very different - HMW CLU-CS
complexes contained approximately the same
number of molecules of CS and CLU, HMW
CLU-FGN
complexes
contained
about
3 molecules of CLU for every FGN molecule,
while
CLU-GST
complexes
contained
5 molecules of GST for each molecule of CLU
(Table 1). These estimated CLU:client protein
ratios were employed when selecting controls for
structural studies of the HMW complexes.
Size Estimation by Dynamic Light
Scattering. The results of DLS were consistent
between 0.1 and 1 mg/ml; representative results
obtained at 0.5 mg/ml are shown (Fig. 4). In
contrast to SEC, DLS was unable to resolve the
differently sized oligomers of CLU in solution;
DLS analysis of CLU samples indicated a
normally distributed particle size. There was no
apparent difference in size between native and
preheated control proteins. The limitations of
DLS in determining the respective diameters of
particles of similar size, resulted in a peak
corresponding to an intermediate size (compared
to the individual proteins) when mixtures of
residual preheated CLU and CS FGN or GST
were analyzed. DLS indicated that SEC purified
HMW CLU-CS and HMW CLU-GST were
approximately six times larger than either of their
respective components, while HMW CLU-FGN
was more than 8 times larger than CLU or FGN
(Fig. 4).
BisANS and Thioflavin T Fluorescence
Assays. The bisANS fluorescence of individual
soluble preheated client proteins showed time
dependent changes. For CS, there was a gradual
increase in fluorescence peaking at 6 h, before
declining at 8 h (Fig. 5A). FGN showed transient
peak fluorescence at 1-2 h before returning to the
level of the unheated control (Fig. 5B). For GST,
the fluorescence was increased over the period 13 h before declining at 4 h (Fig. 5C). In contrast,

the bisANS fluorescence of solutions of CLU
heated alone only displayed a small increase at
1 h and 6 h after heating at 45 ºC (Fig. 5); CLU
did not precipitate under any of these conditions
(data not shown). In all cases, at times when
preheated soluble client protein showed increased
bisANS
fluorescence,
the
corresponding
fluorescence of the respective preheated mixtures
of CLU and client protein showed a lesser change.
This suggests that the interaction between CLU
and partially unfolded client proteins in theses
mixed solutions reduces the extent to which
hydrophobic regions on the client proteins are
exposed to solvent.
Thioflavin T analyses were carried out to
determine if SEC purified complexes possessed
any amyloid-like characteristics (i.e. contained
beta-sheet rich structures). SEC purified HMW
CLU-FGN and CLU-GST complexes and the
relevant native and preheated protein controls all
produced less than 8% of the fluorescence arising
from a sample of lysozyme amyloid present at the
same mass concentration (data not shown).
Circular Dichroism Spectrophotometry.
The CD spectrum for unheated CLU indicated
high -helical content with minima at ~208 nm
and ~222 nm. The molar elipticity at these
wavelengths slightly increased when CLU was
preheated at 43ºC or 60ºC. Under these
conditions, CDSSTR analysis predicted a large
decrease in -helical content, a similarly large
increase in predicted -sheet content and smaller
increases in the predicted contents of -turn and
unordered structure (Fig. 6A; Table 2). However,
heating at 41ºC only produced small increases in
the predicted content of -sheet and -turn
structure (Fig. 6A; Table 2). Preheated CS had a
CD spectrum superimposable on that of unheated
CS (Fig. 6B). In contrast, following heating at
45ºC, FGN showed a change in minima from
~222 nm to ~200 nm, consistent with the
following predicted changes: a small decrease in
-helical content, a moderate decrease in -sheet,
and small increases in -turn and unordered
structure content (Fig. 6C; Table 2). After heating
at 60ºC, GST also showed a change in minima
from that typical of high -helical to a more
disordered structure. CDSSTR predicted a
substantial decrease in -helical content and much
smaller increases in -sheet, -turn and unordered
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structure content (Fig. 6D; Table 2). Comparing
the CD spectra of SEC purified HMW CLU-CS
complexes with those of mixtures of the native or
soluble preheated client proteins suggested that
secondary structure was significantly altered in
HMW CLU-CS complexes (Fig. 6E). This was
largely attributed to a predicted loss of more than
half the native -helical content, compared to the
unheated proteins (Table 2). Analysis of the
spectrum of a mixture of soluble preheated CS
and preheated CLU predicted that, relative to the
CLU-CS complex, the proteins had a smaller
decrease in -helical content and an increase in
unordered structure. In contrast the CD spectrum
for HMW CLU-FGN complexes was virtually
superimposable on that of a mixture of native
CLU and FGN (Fig. 6F; Table 2). However, a
corresponding mixture of preheated CLU and
preheated FGN had a very different CD spectrum,
consistent with the loss of predicted structure for
the individual proteins following heating. It was
evident that the formation of HMW CLU-GST
complexes was accompanied by changes
in secondary structure (Fig. 6G). For these
complexes, relative to a mixture of the native
proteins, there were predicted significant losses of
-helical content, a large increase in -sheet
content, and small increases in -turn and
unordered structure (Table 2). The CD spectrum
and predicted losses of secondary structure were
similar for HMW CLU-GST complexes and a
mixture of soluble preheated GST and CLU.

limit the structure of the complexes and not their
respective molar ratios. However, investigation of
a larger number of client proteins is needed to
confirm this interpretation. SEC indicated that all
types of client protein generated complexes
 4 x 107 Da in vitro (Fig. 2). DLS measurements
suggested that CLU-FGN complexes had a
diameter approximately twice that of CLU-CS or
CLU-GST complexes (approximately 100 versus
50 nm; Fig. 4). At this scale, the soluble
CLU-client protein complexes are very large
indeed, being of a similar size to virus particles.
Measurements of bisANS fluorescence
indicated that heat treatment induced CS, FGN
and GST to expose more hydrophobicity to
solution (Fig. 5). However, at least for FGN and
GST, after 4 h of heating the level of solventexposed hydrophobicity had returned to that of
the respective zero time samples (or less). This
may be because at these later time points a
significant fraction of the client protein had
precipitated from solution and was no longer
available to bind bisANS. The bisANS
fluorescence of solutions of CLU alone heated at
41ºC and 60ºC did not show any significant
changes over the time courses measured (Fig. 5A
& Fig. 5C). Furthermore, although there were
some
statistically
significant
differences
measured, there was no large or consistent change
in the bisANS fluorescence of CLU heated alone
at 45ºC (Fig. 5B). A clear trend in all three cases
is that the bisANS fluorescence of mixtures of
CLU and client protein increased significantly
less during heating than was seen for
corresponding heated solutions of client protein
alone (Fig. 5). Thus, the data shown strongly
suggests that co-incubation with CLU reduced the
extent to which client proteins exposed
hydrophobicity to solution when heated.
Therefore it appears likely that the molecular
interactions involved in the formation of
CLU-client protein complexes either shield
hydrophobic regions on the client protein from
exposure to solution and/or prevent structural
changes that would otherwise occur to result in
their exposure. Previous work has implicated the
binding of CLU to regions of exposed
hydrophobicity on client proteins as an integral
part of its chaperone action (10).
Remarkably, the CD spectra acquired
indicated that HMW CLU-FGN complexes had a

DISCUSSION
Although
CS
(normally
intracellular), FGN (normally extracellular and
highly glycosylated) and GST (recombinant) are
very different proteins with a large discrepancy in
mass (approximately 52, 340 and 23 kDa,
respectively), and the complexes with CLU were
formed using very different conditions (41ºC,
45ºC or 60ºC, respectively), in all cases the
estimated mass stoichiometry of CLU:client
protein in the complexes was about 1:2 (Table 1).
In other words, in each case, CLU formed soluble
complexes in which it "carried" about twice its
own mass in the form of client protein. The molar
ratio of CLU:client protein was quite different for
each type of complex (Table 1), suggesting that
the relative total masses of CLU and client protein
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predicted overall content of the various secondary
structures indistinguishable from that of a mixture
of native CLU and FGN at the same
concentrations (Fig. 6F). The most likely
interpretation of this result is that, under the
conditions tested, the interaction between CLU
and FGN resulted in a mutual stabilization of
secondary structures. Interestingly, the situation
was quite different when examining complexes
formed between CLU and CS or GST. In these
cases, the predicted loss of overall -helical
structure in the complexes was the same or
greater than that in the corresponding mixture of
preheated CLU and soluble preheated client
protein. However, the complexes had more
predicted -sheet content and slightly less -turn
and unordered structure than the corresponding
mixture of previously heated proteins (Table 2).
The differences observed may be due to the
differing inherent stabilities of the client proteins
and the nature of secondary structure of unfolded
intermediate states they display.
Especially
under
conditions
of
pathological stress, but also under normal
physiological conditions, it is likely that in
extracellular fluids CLU-client protein complexes
will form as a mechanism to combat the
development of insoluble protein aggregates
which can give rise to a variety of disease
conditions (8). Results presented here suggest that
CLU may interact with unfolding proteins at
different points along their respective unfolding
pathways. Depending on the point at which this
interaction occurs, CLU may maintain the native
secondary structures of the client protein or
stabilize the client in some other non-native but
stable conformation. The interactions between
CLU and the client protein are likely to involve
CLU
shielding
regions
of
exposed
hydrophobicity.
Physiological
factors
such
as
macromolecular crowding and shear stress are
likely to favor protein aggregation in vivo
compared to low concentrations of purified
proteins in simple buffers (2,29,30). Thus, like
many other studies of chaperone action, we used
elevated temperature to induce client proteins to
unfold and interact with CLU in vitro. CLU is
very heat-stable and heating up to at least 60ºC
does not inhibit its chaperone action (9,12).
Mammals experience sporadic increases in body

temperature as a result of physical activity (31),
environmental exposure (32) and infection (33);
fevers of up to 42ºC have been reported (34).
Thus, the mild heat stress (41ºC) used to induce
the precipitation of CS is encountered
physiologically. Despite the differing conditions
required for their formation in vitro, all three
types of complexes shared the following features:
a CLU:client protein mass ratio of 1:2, very large
size ( 4 x 107 Da by SEC, and diameters of
50-100 nm by DLS), and reduced exposed
hydrophobicity on the client protein (compared to
client protein heated alone). It appears reasonable
to expect that these shared characteristics give us
important insights into the biophysical properties
of CLU-client protein complexes in general and
add to our mechanistic understanding of the
chaperone action of CLU.
In unpublished work, we have shown that
when human plasma is "stressed" by gentle
rotation for 10 days at 37ºC, the plasma contains
CLU-FGN complexes (detected by sandwich
ELISA), and when fractionated by SEC both CLU
and FGN are present in fractions corresponding to
molecules  4 x 107 Da (manuscript in
preparation). Thus, it appears likely that CLUclient protein complexes generated in situ in
plasma are likely to include species of the sizes
reported here for complexes formed in vitro from
purified proteins. It is not possible to purify intact
CLU-client protein complexes from plasma by
immunoaffinity chromatography because the
harsh elution conditions (2M GdHCl) will at least
partly disrupt intermolecular interactions.
Inappropriately aggregating proteins can
be cytotoxic and also give rise to large
pathological deposits which can interfere with
organ/tissue function (35-39). In vivo, the
sequestration of misfolded proteins into large,
soluble complexes with extracellular chaperones
like CLU is likely to be the first step in preventing
them from forming toxic or otherwise
pathological aggregates. On the basis of evidence
reviewed elsewhere, we have proposed that these
soluble complexes are probably rapidly cleared
from the body by receptor-mediated endocytosis
and subsequent lysosomal degradation (8,40). It
will be important to demonstrate that this process
operates in a whole animal model - this work is
currently underway.
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The abbreviations used are: CLU, clusterin; HMW, high molecular weight; CS, citrate synthase; FGN,
fibrinogen; GST, glutathione-S-transferase; sHSP, small heat shock protein; Hsp, heat shock protein;
LDL, low density lipoprotein; IgG, immunoglobulin gamma; SEC, size exclusion chromatography; G7,
anti-human clusterin monoclonal antibody; FPLC, fast protein liquid chromatography; SDS-PAGE,
sodium dodecyl sulfate polyacrylamide gel electrophoresis; BSA, bovine serum albumin; ELISA, enzymelinked immunosorbent assay; PBS, phosphate buffered saline; bisANS, 4,4-dianilino-1,1-binaphthyl-5,5disulfonic acid; AFU, arbitrary fluorescence units.
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TABLE LEGENDS
Table 1. Approximate mass and molar ratios of client protein to CLU in SEC purified HMW
CLU-CS, HMW CLU-FGN and HMW CLU-GST complexes. SEC purified HMW CLU-client
protein complexes were separated by reducing SDS-PAGE, stained with Coomasie blue, and analyzed
using densitometry. The CLU:client protein ratios were calculated as described in the
EXPERIMENTAL METHODS. The ratios shown are the calculated means of three independent
estimates.
Table 2. CDSSTR predictions of secondary structural content, based on far-UV CD data, for
(i) unheated or preheated client proteins and CLU, (ii) mixtures of client protein and CLU (unheated or
separately preheated), and (iii) SEC purified HMW CLU-client protein complexes. Protein samples were
heated using the same conditions as in the precipitation assays (see EXPERIMENTAL PROCEDURES).

FIGURE LEGENDS
Fig. 1. CLU inhibits the heat-induced aggregation of CS, FGN and GST. (A) 6.0 μM CS was
incubated at 41ºC in the presence of 6.6 μM CLU ( ) or 6.5 μM BSA (x). 6.0 μM CS () was also
incubated alone under the same conditions. (B) 6 μM FGN was incubated at 45ºC in the presence of
6.5 μM CLU ( ) or 6.5 μM BSA (x). 6 μM FGN () was also incubated alone under the same
conditions. (C) 20 μM GST was incubated at 60ºC in the presence of 3.2 μM CLU ( ) or 3.2 μM
BSA (x). 20 μM GST (), 3.2 μM CLU ( ) and 3.2 μM BSA () were also incubated alone under
the same conditions. The turbidity associated with protein precipitation (A360) was monitored. Data
points shown are the mean of triplicate measurements and are representative of at least three
independent experiments.
Fig. 2. CLU forms HMW complexes with client proteins undergoing stress in vitro. Absorbance
traces (A280 nm) for SEC. (A) Samples analyzed were unheated and preheated CS and CLU, an
unheated mixture of CS and CLU, a mixture of preheated CS (*CS) and preheated CLU (*CLU), and
a heated mixture of CS and CLU (CS + CLU). (B) Samples analyzed were unheated and preheated
FGN and CLU, an unheated mixture of FGN and CLU, a mixture of preheated FGN (*FGN) and
preheated CLU (*CLU), and a heated mixture of FGN and CLU (FGN + CLU). (C) Samples analyzed
were unheated and preheated GST and CLU, an unheated mixture of GST and CLU, a mixture of
preheated GST (*GST) and preheated CLU (*CLU), and a heated mixture of GST and CLU (GST +
CLU). The positions of molecular mass standards (kDa) are shown and the exclusion volume (Vo)
corresponds to molecules  4x 107 Da. The concentration of proteins and the heating conditions used
were in all cases the same as in the precipitation assays (see EXPERIMENTAL PROCEDURES). The
traces shown are representative of more than three independent experiments.
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Fig. 3. Histograms showing the results of sandwich ELISA demonstrating HMW CLU-client
protein complexes formed in vitro. Samples analyzed were (A) SEC exclusion limit fraction from a
heated mixture of CS and CLU (HMW CLU-CS), preheated CS (*CS), preheated CLU (*CLU), and a
mixture of *CS and *CLU; (B) SEC exclusion limit fraction from a heated mixture of FGN and CLU
(HMW CLU-FGN), preheated FGN (*FGN), preheated CLU (*CLU), and a mixture of *FGN and
*CLU; (C) SEC exclusion limit fraction from a heated mixture of GST and CLU (HMW CLU-GST),
preheated GST (*GST), preheated CLU (*CLU), and a mixture of *GST and *CLU. The conditions
used to generate the complexes and the preheated proteins, and to perform SEC, were as described in
EXPERIMENTAL PROCEDURES. Values shown represent the mean of 3 replicates ± standard
error. + Denotes significantly greater A490 nm compared to all preheated controls (Tukey HSD,
p  0.01).

Fig. 4. Dynamic light scattering estimates of the mean diameters of HMW CLU-client protein
complexes and other proteins. Samples analyzed were SEC purified HMW complexes of CLU-CS,
CLU-FGN and CLU-GST, unheated CS, FGN, GST and CLU, preheated CS, FGN, GST and CLU
(*CS, *FGN, *GST and *CLU, respectively), and mixtures of the preheated client proteins and *CLU.
The conditions used to generate the complexes and the preheated proteins were as described in
EXPERIMENTAL PROCEDURES. There was no significant difference in the mean diameters of
*CLU preheated at 41ºC, 45ºC or 60ºC (only data for *CLU preheated at 60ºC is shown). Histograms
represent mean diameter ± range of 9 normally distributed curves.

Fig. 5. Plots showing time-dependent changes in bisANS fluorescence during heating of CS,
FGN, GST ± CLU, and CLU alone, in arbitrary fluorescence units (AFU). Samples analyzed were
(A) CS or CLU alone or CS co-incubated with CLU, (B) FGN or CLU alone or FGN co-incubated
with CLU, (C) GST or CLU alone or GST co-incubated with CLU. Data points shown represent the
mean fluorescence of 3 replicates ± standard error. For each plot the 0 h time value has been
normalized to a value of 10,000 AFU. The conditions used to generate the complexes and the
preheated proteins were as described in EXPERIMENTAL PROCEDURES. + Denotes increased
bisANS fluorescence compared to the respective 0 h time value (Tukey HSD, p  0.01).

Fig. 6. Far-UV CD spectra. Samples analyzed were (A) CLU and *CLU preheated as indicated,
unheated and preheated (B) CS, (C) FGN, and (D) GST; (E) SEC purified HMW CLU-CS and mixtures of
unheated or preheated CS and CLU, (F) SEC purified HMW CLU-FGN and mixtures of unheated or
preheated FGN and CLU, and (G) SEC purified HMW CLU-GST and mixtures of unheated or preheated
GST and CLU. The conditions used to generate the complexes and the preheated proteins were as
described in EXPERIMENTAL PROCEDURES. The data shown are means of six scans.
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Table 1
HMW
Complex

Conditions

Mass Ratio
(CLU:Client)

Standard
Error
(±, n = 3)

CLU-CS
CLU-FGN
CLU-GST

9 h, 41°C
12 h, 45°C
50 min, 60°C

1 : 1.81
1 : 1.88
1 : 2.11

0.027
0.146
0.168

12

Molar Ratio
(CLU:client)
1 : 1.17
1 : 0.34
1 : 5.14

Standard
Error
(±, n = 3)
0.01
0.03
0.41

Table 2
Sample

Helix

Sheet

Turns

Unordered

CS
*CS
FGN
*FGN
GST
*GST
CLU
*CLU 41°C
*CLU 45°C
*CLU 60°C
HMW CLU-CS
CLU:CS
*CLU:*CS
HMW CLU-FGN
CLU:FGN
*CLU:*FGN
HMW CLU-GST
CLU:GST
*CLU:*GST

69.45 ± 1.39
63.95 ± 0.98
11.34 ± 0.32
7.09 ± 0.15
13.88 ± 0.24
7.36 ± 0.22
34.19 ± 0.10
39.26 ± 0.23
15.75 ± 0.22
14.69 ± 0.21
30.59 ± 0.21
63.59 ± 0.67
46.98 ± 0.41
26.25 ± 0.10
26.99 ± 0.09
9.38 ± 0.17
11.55 ± 0.24
33.80 ± 0.18
11.78 ± 0.25

7.25 ± 1.36
11.43 ± 1.10
41.36 ± 0.77
32.90 ± 0.12
33.88 ± 0.52
34.32 ± 0.39
18.70 ± 0.17
17.18 ± 0.39
30.55 ± 0.47
31.52 ± 0.43
21.26 ± 0.37
10.15 ± 0.80
15.69 ± 0.64
22.67 ± 0.18
22.52 ± 0.19
32.49 ± 0.22
36.83 ± 0.39
21.66 ± 0.35
29.48 ± 0.38

7.70 ± 1.01
11.62 ± 0.84
20.21 ± 0.69
25.25 ± 0.25
21.81 ± 0.54
24.58 ± 0.50
19.89 ± 0.19
16.81 ± 0.34
23.83 ± 0.49
23.00 ± 0.45
18.84 ± 0.28
10.45 ± 0.78
15.27 ± 0.51
21.21 ± 0.19
21.15 ± 0.18
23.85 ± 0.28
21.29 ± 0.38
18.54 ± 0.40
25.93 ± 0.49

15.93 ± 1.16
12.92 ± 1.05
26.72 ± 1.06
33.58 ± 0.31
29.96 ± 0.66
32.72 ± 0.56
26.69 ± 0.25
26.57 ± 0.52
29.39 ± 0.61
30.38 ± 0.63
29.33 ± 0.44
15.35 ± 1.08
22.45 ± 0.79
28.82 ± 0.24
28.57 ± 0.27
33.64 ± 0.27
29.32 ± 0.47
25.75 ± 0.54
32.70 ± 0.46
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